These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21185050)

  • 1. Terminal modifications of norovirus P domain resulted in a new type of subviral particles, the small P particles.
    Tan M; Fang PA; Xia M; Chachiyo T; Jiang W; Jiang X
    Virology; 2011 Feb; 410(2):345-52. PubMed ID: 21185050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noroviral P particle: structure, function and applications in virus-host interaction.
    Tan M; Fang P; Chachiyo T; Xia M; Huang P; Fang Z; Jiang W; Jiang X
    Virology; 2008 Dec; 382(1):115-23. PubMed ID: 18926552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small P particles formed by the Taiwan-native norovirus P domain overexpressed in Komagataella pastoris.
    Chen YL; Chang PJ; Huang CT
    Appl Microbiol Biotechnol; 2018 Nov; 102(22):9707-9718. PubMed ID: 30187100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterologous expression of human norovirus GII.4 VP1 leads to assembly of T=4 virus-like particles.
    Devant JM; Hofhaus G; Bhella D; Hansman GS
    Antiviral Res; 2019 Aug; 168():175-182. PubMed ID: 31145925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural heterogeneity of a human norovirus vaccine candidate.
    Devant JM; Hansman GS
    Virology; 2021 Jan; 553():23-34. PubMed ID: 33202318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigenic and Cryo-Electron Microscopy Structure Analysis of a Chimeric Sapovirus Capsid.
    Miyazaki N; Taylor DW; Hansman GS; Murata K
    J Virol; 2015 Dec; 90(5):2664-75. PubMed ID: 26699644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production and characterization of virus-like particles and the P domain protein of GII.4 norovirus.
    Koho T; Huhti L; Blazevic V; Nurminen K; Butcher SJ; Laurinmäki P; Kalkkinen N; Rönnholm G; Vesikari T; Hytönen VP; Kulomaa MS
    J Virol Methods; 2012 Jan; 179(1):1-7. PubMed ID: 21600929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production of Brazilian human norovirus VLPs and comparison of purification methods.
    Lamounier TA; de Oliveira LM; de Camargo BR; Rodrigues KB; Noronha EF; Ribeiro BM; Nagata T
    Braz J Microbiol; 2015; 46(4):1265-8. PubMed ID: 26691489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epitope mapping of histo blood group antigens bound to norovirus VLPs using STD NMR experiments reveals fine details of molecular recognition.
    Fiege B; Leuthold M; Parra F; Dalton KP; Meloncelli PJ; Lowary TL; Peters T
    Glycoconj J; 2017 Oct; 34(5):679-689. PubMed ID: 28823097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanobody binding to a conserved epitope promotes norovirus particle disassembly.
    Koromyslova AD; Hansman GS
    J Virol; 2015 Mar; 89(5):2718-30. PubMed ID: 25520510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-resolution cryo-EM structures of outbreak strain human norovirus shells reveal size variations.
    Jung J; Grant T; Thomas DR; Diehnelt CW; Grigorieff N; Joshua-Tor L
    Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12828-12832. PubMed ID: 31182604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs.
    Kocher J; Bui T; Giri-Rachman E; Wen K; Li G; Yang X; Liu F; Tan M; Xia M; Zhong W; Jiang X; Yuan L
    J Virol; 2014 Sep; 88(17):9728-43. PubMed ID: 24920797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive characterization of a major capsid protein derived from a documented GII.6 norovirus strain.
    Zheng L; Wang W; Liu J; Huo Y; Qin C; Wang M; Shen S
    Arch Virol; 2017 Dec; 162(12):3863-3868. PubMed ID: 28866835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phylogenetic and biological characterizations of a GI.3 norovirus.
    Zheng L; Zhang H; Ma J; Liu J; Ma S; Wang M; Huo Y
    Infect Genet Evol; 2020 Nov; 85():104554. PubMed ID: 32927119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Norovirus Uses Bile Salts To Escape Antibody Recognition While Enhancing Receptor Binding.
    Williams AN; Sherman MB; Smith HQ; Taube S; Pettitt BM; Wobus CE; Smith TJ
    J Virol; 2021 Jun; 95(13):e0017621. PubMed ID: 33827952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural analysis of determinants of histo-blood group antigen binding specificity in genogroup I noroviruses.
    Shanker S; Czako R; Sankaran B; Atmar RL; Estes MK; Prasad BV
    J Virol; 2014 Jun; 88(11):6168-80. PubMed ID: 24648450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and characterization of the major capsid protein derived from a GII.6 norovirus strain isolated in China.
    Huo Y; Zheng L; Chen X; Ge L; Wang Y
    Microb Pathog; 2017 Apr; 105():131-137. PubMed ID: 28219831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequence addition to the N- or C-terminus of the major capsid protein VP1 of norovirus affects its cleavage and assembly into virus-like particles.
    Ma J; Liu J; Zheng L; Wang C; Zhao Q; Huo Y
    Microb Pathog; 2022 Aug; 169():105633. PubMed ID: 35700875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus.
    Tan M; Jiang X
    Nanomedicine (Lond); 2012 Jun; 7(6):889-97. PubMed ID: 22734641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for broad detection of genogroup II noroviruses by a monoclonal antibody that binds to a site occluded in the viral particle.
    Hansman GS; Taylor DW; McLellan JS; Smith TJ; Georgiev I; Tame JR; Park SY; Yamazaki M; Gondaira F; Miki M; Katayama K; Murata K; Kwong PD
    J Virol; 2012 Apr; 86(7):3635-46. PubMed ID: 22278249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.